During the PFATS meeting at the NFL Medical Summit, the inventors of sustained acoustic medicine will demonstrate the technology and present research showing its effectiveness in accelerating soft tissue healing.
Read More-Received positive feedback on New Drug Application submission via the 505(b)(2) pathway
-Company leveraging existing human pharmacokinetic data with TH104
-Advancing CMC plan to meet requirements of a New Drug Application
Read More
The total net revenue for the year ended December 31, 2024 of approximately $11.7 million for prescription and non-prescription products, including license revenue, increased approximately 20% versus net revenue of $9.8 million for the year ended December 31, 2023
The total net Q4 2024 revenue of approximately $3.5 million for prescription and non-prescription products, including license revenue, increased approximately 13% versus net Q3 2024 revenue of $3.1 million and 53% versus net Q4 2023 revenue of $2.3 million
Jaguar expects first results in Q2 2025 of proof-of-concept (POC) investigator-initiated trials (IIT) of crofelemer for the rare diseases short bowel syndrome with intestinal failure and microvillus inclusion disease, with additional POC IIT results expected throughout 2025
FDA meeting in the second quarter of 2025 on the statistically significant results of the Phase 3 OnTarget trial of crofelemer in the prespecified subgroup of patients with breast cancer
REMINDER: Jaguar to host investor webcast Monday, March 31st at 8:30 a.m. Eastern regarding Q4 2024 financials and company updates; Click here to register for webcast
Read MoreCompany Delivers Quarterly Revenue of $2.4 Million as Projected or $5.4 Million for full-year 2024
Quarterly Net Loss and Earnings per Diluted Share of $5.8 Million and $7.26
Quarterly Adjusted EBITDA Loss of $1.9 Million Reflects 42% Improvement YOY and 19% Sequentially
Stockholders' Equity Was $7.1 Million at Year End
Pending Acquisitions Remain on Track; TRNR Expects More than $50M in 2025 Pro Forma Revenue
Read More
"The DEA's marijuana approach is stuck in an outdated ‘war on drugs' mentality," said Duane Boise CEO of MMJ International Holdings. "While lawmakers push for medical progress, the DEA's red tape is suffocating innovation."
DEA officials, including Matt Strait and Thomas Prevoznik, have been accused of imposing unnecessary hurdles, such as slow-walking API Bulk Manufacturing registrations, and imposing opaque approval processes while patients continue to suffer.
Read MoreCompletion of unbuzzdTM Clinical Trial and Multiple Sclerosis Drug Lucid-21-302 Phase 1 Trial Advance Company's Pipeline of Products and Assets
Read More
Despite differences in characteristics and treatment, the pFCG test distinguished risk of the primary ischemic endpoint to a similar extent in the 2 groups.
No significant association was observed between pFCG and risk of bleeding.
Canalevia®-CA1 (crofelemer delayed-release tablets) is the first and only treatment for CID in dogs to receive any type of approval from the FDA
In dogs undergoing chemotherapy, as is the case with people undergoing cancer treatment, diarrhea is a highly neglected and unmet medical need
Read MorePartnership Raises FORME's Visibility with Affluent Customers, Highlights Brand's Seamless Integration into Premium Hospitality and Travel Environments
Installation adds to Hospitality Customers such as Four Seasons, Bulgari and Mandalay Bay Resort
Read MoreCandid Health Reports on Security, Availability, and Confidentiality Standards Established by The American Institute of Certified Public Accountants (AICPA) for its Candid Health Revenue Cycle Automation Platform.
Read MoreThe statistically significant responder analysis results for Mytesi® (crofelemer) in the OnTarget study's prespecified subgroup of patients with breast cancer were the subject of a December 2024 poster presentation at the San Antonio Breast Cancer Symposium
Late-breaker abstract recently submitted to the Multinational Association of Supportive Care in Cancer (MASCC) shows additional significant results for breast cancer subgroup
The American Cancer Society expects 316,950 new cases of breast cancer diagnosed in women in the US in 2025, and it's estimated that there were 4 million US women with a history of invasive breast cancer in 2022
Read More
The global sexual wellness market is projected to surpass $125 billion by 2026, with the supplement industry experiencing rapid growth as consumers seek natural solutions for enhanced performance and vitality.
Read More
Duane Boise, CEO of MMJ International Holdings, expressed frustration over the contrasting approaches of federal agencies, stating, "While the FDA is facilitating medical innovation, the DEA's hindrance not only blocks scientific progress but also contradicts directives aimed at revitalizing domestic manufacturing." This situation starkly contrasts with the "Buy American" initiative endorsed by President Trump in 2020, which was intended to strengthen U.S. drug production capabilities and reduce dependence on foreign manufacturers.
Read MoreClick here to register for Jaguar's March 27 virtual presentation at the Emerging Growth Conference
Click here to register for Jaguar's March 31 investor webcast
Company plans to file its annual report on March 31, 2025 on Form 10-K for the year ended December 31, 2024
Read More
As the federal government seeks to cut Medicaid expenses, the groundbreaking smart pill bottle technology can help by providing physicians, pharmacists and industry with improved medication adherence and prescription oversight and accountability.
Read More
